

# Repeated in field-SBRT for lung and liver tumors



**DEGRO AG – Stereotaxie** 

Principle Investigator: PD Dr. Panagiotis Balermpas
Department of Radiation Oncology, UniversitätsSpital Zürich

#### Background



- Thoracal/abdominal re-irradiation challenging clinical situation
- Most existing data: "low dose" palliative regimens for lung Re-RT, providing good symptom control<sup>1</sup>
- Also "Full dose" data for small volumes < 100 cc, but mostly originating from fractionated regimens<sup>1</sup>
- Proton-implementation for Re-RT does not seem to provide any benefit, but considerable toxicity<sup>2</sup>
- Series using SBRT for Re-RT report good tumor control, but higher toxicity compared to primary setting<sup>3</sup>
- Data for Re-SBRT limited to very small retrospective series, showing serious toxicity<sup>4</sup> and no data available for liver localization

<sup>1</sup>Drodge Ann Palliat Med 2014

<sup>2</sup>Chao, JTO, 2017

<sup>3</sup>De Bari Cancer Treatment Reviews 2015

<sup>4</sup>Peulen Radiother Oncol 2011



### Background: SBRT for lung reirradiation

Local control @ 1-2 years	Overall survival @ 1-2 years	G3-5 pneumonitis
52% - 92%	59% - 88%	3 – 30%
81%	68%	None

De Bari et al. Cancer Treatment Reviews 2015


Kennedy et al. Radiother Oncol 2019

➤ Overall effective and well tolerated

#### Background: Re-SBRT after SBRT



Retrospective analysis of 32 patients treated with 2 (n=29), 3 (n=2) or 4 (n=1) SBRT courses



➤ SBRT reirradiation for central recurrences strongly discouraged!





- Systematic report of multicenter data including patterns of care, feasibilty and toxicity are missing
- No standard and no consensus for the optimal treatment for these, mostly inoperable patients
- Absolutely no reliable data concerning liver lesions
- Deferral of systemic treatment and possible chance for cure

#### Primary objective

To analyze the toxicity and efficacy of a second in-field course of SBRT for

lung and liver lesions

#### Project plan



- establish a database of patients treated with a second course of stereotactic body radiotherapy (SBRT as defined by the DEGRO-AG)
- PTV of the second SBRT should have at least partial overlap with a previous SBRT-PTV
  pooled analysis of patient records including radiotherapy plans as DICOM files,
  transferred as anonymized DICOM files to the USZ transfer-server
- radiotherapy plans of both courses electronically available, centrally collected and evaluated, calculation of a summation plan (in both EQD2 and BED)
- Data stratified according to anatomic localization, re-RT volume, histology, dose-features and a detailed outcome analysis will be performed





#### The members would need to submit data:

- **1.Baseline information** (Tumor type, other metastatic sites, previous treatments) for both SBRT courses
- **2.Outcome** data, i.e. acute toxicity, late toxicity, local control, progression-free survival, overall survival
- 3.Complete **RT-plans** including **DICOM**-files, dose-/volume information for organs at risk and for the GTV and the PTV for both SBRT courses

### Timeline - Stand of the project 11/2019



- Letter of intent circulated
- Ethical committee approval for Germany submitted (Oliver Blanck)
- USZ-transfer server already functioning

12/2018 server link, project outline and table with parameters circulated

12/2018-03/2019 Local ethical approvals in partner sites

Since 03/2019 data collection

Q4: Last call for data/case collection (central data evaluation already started)

Q1-Q2 2020 1st publication

All clinics providing data can name one co-author on each publication due

Due to the complexity of the project; clinics providing five or more patients can name 2 co-authors on each publication.


## Stand of the project 06/2019 centers and numbers



26 centers expressed interest/ 7 already participating/ cases not completely validated yet!

Centers already recruiting	Cases Lung (n)	Cases Liver (n)
Berlin	5	
Freiburg	1	5
Freising	1	
Güstrow	5	7
Mannheim	1	1
Salzburg	2	
Zürich	25	3
TOTAL	40	16

Kennedy et al. recently reported about 21 patients treated with Re-SBRT in the lung (Radiother Oncol, 2019)



#### Contact address for interested sites: Panagiotis.balermpas@usz.ch



**DEGRO AG – Stereotaxie**